Focus on Anti-Tumour Necrosis Factor (TNF)-α-Related Autoimmune Diseases

被引:22
作者
Lopetuso, Loris Riccardo [1 ,2 ,3 ]
Cuomo, Claudia [1 ]
Mignini, Irene [1 ]
Gasbarrini, Antonio [1 ,4 ]
Papa, Alfredo [1 ,4 ]
机构
[1] IRCCS, Ctr Diag & Treatment Digest Dis, Gastroenterol Dept, CEMAD,Fdn Policlin Gemelli, I-00168 Rome, Italy
[2] G DAnnunzio Univ Chieti Pescara, Dept Med & Ageing Sci, I-66100 Chieti, Italy
[3] G DAnnunzio Univ Chieti Pescara, Ctr Adv Studies & Technol CAST, I-66100 Chieti, Italy
[4] Catholic Univ, Sch Med, Dept Translat Med & Surg, I-00168 Rome, Italy
关键词
infliximab; adalimumab; etanercept; certolizumab pegol; golimumab; autoimmune diseases; inflammatory bowel disease; paradoxical reactions; ANTI-TNF-ALPHA; INFLAMMATORY-BOWEL-DISEASE; INFLIXIMAB-RELATED HEPATITIS; INTERSTITIAL LUNG-DISEASES; DRUG-INDUCED LUPUS; RHEUMATOID-ARTHRITIS; CROHNS-DISEASE; PULMONARY SARCOIDOSIS; FIBROSING ALVEOLITIS; ETANERCEPT THERAPY;
D O I
10.3390/ijms24098187
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Anti-tumour necrosis factor (TNF)-a agents have been increasingly used to treat patients affected by inflammatory bowel disease and dermatological and rheumatologic inflammatory disorders. However, the widening use of biologics is related to a new class of adverse events called paradoxical reactions. Its pathogenesis remains unclear, but it is suggested that cytokine remodulation in predisposed individuals can lead to the inflammatory process. Here, we dissect the clinical aspects and overall outcomes of autoimmune diseases caused by anti-TNF-a therapies.
引用
收藏
页数:13
相关论文
共 106 条
[1]   Acute Kidney Injury due to Renal Sarcoidosis during Etanercept Therapy: A Case Report and Literature Review [J].
Akiyama, Mitsuhiro ;
Kaneko, Yuko ;
Hanaoka, Hironari ;
Kuwana, Masataka ;
Takeuchi, Tsutomu .
INTERNAL MEDICINE, 2015, 54 (09) :1131-1134
[2]   Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab [J].
Allanore, Y. ;
Devos-Francois, G. ;
Caramella, C. ;
Boumier, P. ;
Jounieaux, V. ;
Kahan, A. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (06) :834-835
[3]  
Almoallim Hani, 2012, Open Rheumatol J, V6, P315, DOI 10.2174/1874312901206010315
[4]   Generalized Pustular Psoriasis Induced by Infliximab in a Patient With Inflammatory Bowel Disease [J].
Almutairi, Dalal ;
Sheasgreen, Christopher ;
Weizman, Adam ;
Alavi, Afsaneh .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2018, 22 (05) :507-510
[5]   Oral Lichen Planus in IBD Patients: A Paradoxical Adverse Effect of Anti-TNF-α Therapy [J].
Andrade, Patricia ;
Lopes, Susana ;
Albuquerque, Andreia ;
Osorio, Filipa ;
Pardal, Joana ;
Macedo, Guilherme .
DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (09) :2746-2749
[6]   C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab [J].
Ashok, Dayavathi ;
Dubey, Shirish ;
Tomlinson, Ian .
CLINICAL RHEUMATOLOGY, 2008, 27 (02) :261-264
[7]   Over-expression of tumor necrosis factor-α in vitiligo lesions after narrow-band UVB therapy: an immunohistochemical study [J].
Attwa, Enayat ;
Gamil, Hend ;
Assaf, Magda ;
Ghonemy, Sohair .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2012, 304 (10) :823-830
[8]   Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis [J].
Atzeni, Fabiola ;
Boiardi, Luigi ;
Salli, Salvatore ;
Benucci, Maurizio ;
Sarzi-Puttini, Piercarlo .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2013, 9 (07) :649-657
[9]   Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study [J].
Bae, Jung Min ;
Kim, Miri ;
Lee, Han Hee ;
Kim, Ki-Jo ;
Shin, Hyoseung ;
Ju, Hyun Jeong ;
Kim, Gyong Moon ;
Park, Chul Jong ;
Park, Hyun Jeong .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (04) :768-774
[10]   Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics [J].
Barthel, Deborah ;
Ganser, Gerd ;
Kuester, Rolf-Michael ;
Onken, Nils ;
Minden, Kirsten ;
Girschick, Hermann Josef ;
Hospach, Anton ;
Horneff, Gerd .
JOURNAL OF RHEUMATOLOGY, 2015, 42 (11) :2160-2165